The debt-for-debt refinancing (secured to unsecured) and extended cash runway through 2028 are credit-positive for preferred holders. Monitor the stock price relative to the $124.53 conversion threshold, sustained trading above may trigger conversion and dilute common equity, which would be neutral for the preferred. The large total convertible balance (~$701M) could pressure the common if the stock rallies significantly, but preferred dividend coverage improves with the term loan repayment.
CELC drugs
CELC drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 9 $92.59entry
- T+1 · 5mo ago −4.70%α −3.12% · $88.24
- T+5 · 5mo ago −4.70%α −7.11% · $88.24
- T+20 · 4mo ago +24.98%α +23.53% · $115.72
- T+60 · 3mo ago +3.90%α +0.09% · $96.20
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Celcuity closed a $500M (plus $75M over-allotment) 0.250% convertible senior notes offering on June 8, 2026, executing the second supplemental indenture and underwriting agreement filed as exhibits to this 8-K. Net proceeds of ~$484.3M will repay the $137.9M secured term loan (de-levering to zero secured debt) and fund working capital, commercial launch, and pipeline through 2028. This follows preliminary filings from June 3 and June 5; the combination of large unsecured convert issuance (~$701M in total converts including prior tranches) with secured debt repayment is credit-positive for the capital structure but adds substantial leverage and potential dilution.
Key Facts
- $575M total (initial $500M + $75M over-allotment) of 0.250% convertible senior notes due 2032 issued
- Initial conversion rate of 8.0302 shares per $1,000 principal, equal to ~$124.53 conversion price
- Initial conversion premium was 57.2% above the $79.23 stock price (based on preliminary pricing; final terms confirmed in indenture)
- Net proceeds of ~$484.3M will fully repay the $137.9M secured term loan and fund clinical/commercial pipeline
- The de-levering to $0 secured debt is a significant credit event for the preferred equity structure
- Aggregate convertible debt now totals ~$701M ($201M prior + $575M new), adding material leverage and potential stock dilution
- Underwriters purchased at 97.0% of principal; Jefferies, J.P. Morgan, TD Cowen, Guggenheim led the syndicate
Financial Impact
Deleveraging of $137.9M secured term loan (~$484.3M net proceeds) is positive credit event, but raises total convertible debt to ~$701M (potential for substantial dilution if converted; initial conversion rate implies 4.62M shares on base of ~28M outstanding at the $124.53 conversion price plus make-whole adjustments up to 11.2422 shares per $1,000 = ~6.46M shares fully diluted).
Risk Factors
- ~$701M in total convertible debt creates significant potential common stock dilution if conversion threshold is met
- Reliance on capital markets for future financing needs; large unsecured convert exposes balance sheet to conversion risk
- Execution risk in commercial launch and pipeline development given funds deployment timeline
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 2 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-027717 |
| Exhibit: ex1-1.htm | 0001493152-26-027717 |
Track record
26 reports on CELC
7 of 13 bullish or bearish reports moved the stock their way by T+5. Best: +26.84% at T+20 after the Jun 11, 2026 report. 9 of 13 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $62.58 Now $60.57 −3.21% settles Nov 23
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $64.37 Now $60.57 −5.90% settles Nov 23
- Nov 9, 20267d ago Press Release Bullish 5/10 Entry $70.37 to $60.57 Now $60.57 −13.93% ▼ −13.93% −12.23% vs SPY
- Nov 5, 202611d ago 8-K Neutral 5/10 No price data
- Nov 5, 202611d ago Press Release Neutral 5/10 Entry $66.79 to $64.37 Now $60.57 −9.31% ▼ −3.62% −6.22% vs SPY
- Nov 2, 202614d ago Institutional Cluster Neutral 3/10 Entry $69.72 to $67.05 Now $60.57 −13.12% ▼ −3.83% −3.24% vs SPY
- Oct 24, 202623d ago Press Release Bullish 6/10 Entry $65.80 to $69.13 Now $60.57 −7.95% ▲ +5.06% +6.32% vs SPY
- Oct 5, 20266w ago 3 Neutral 2/10 Entry $71.25 to $63.19 Now $60.57 −14.99% ▼ −11.31% −11.17% vs SPY
- Oct 2, 20266w ago 8-K Neutral 2/10 Entry $72.10 to $67.94 Now $60.57 −15.99% ▼ −5.77% −6.93% vs SPY
- Sep 30, 20266w ago 8-K Bullish 6/10 Entry $79.52 to $65.78 Now $60.57 −23.83% ▼ −17.28% −19.19% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers